(Q45175627)

10 December 2017

0 references

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis (English)

1 reference

10 December 2017

0 references

1 reference

3

1 reference

10 December 2017

6

1 reference

10 December 2017

1

Peter Jüni

1 reference

10 December 2017

5

Paul A Dieppe

1 reference

10 December 2017

Linda Nartey

2

1 reference

10 December 2017

Rebekka Sterchi

series ordinal

4

1 reference

10 December 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

10 December 2017

1 reference

10 December 2017

volume

364

1 reference

10 December 2017

issue

9450

1 reference

10 December 2017

page(s)

2021-2029

1 reference

Failing the public health--rofecoxib, Merck, and the FDA.

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Risk of cardiovascular events associated with selective COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Risk of myocardial infarction associated with selective COX-2 inhibitors: questions remain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Association between naproxen use and protection against acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Lessons from the withdrawal of rofecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protoco

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Onset of pain relief with rofecoxib in chronic low back pain: results of two four-week, randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

The Risk of Gastrointestinal Bleed, Myocardial Infarction, and Newly Diagnosed Hypertension in Users of Meloxicam, Diclofenac, Naproxen, and Piroxicam

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Vioxx: an unequal partnership between safety and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Selective COX-2 Inhibitors, NSAIDs, aspirin, and myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

1 reference

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Cyclooxygenase inhibition and thrombogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

Commentary: hormone replacement therapy and coronary heart disease: four lessons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917514-4

7 January 2021

10.1016/S0140-6736(04)17514-4

Identifiers

DOI

1 reference

10 December 2017

1 reference